Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.

Arun RajanHoussein Abdul SaterOsama RahmaRichy AgajanianWiem LassouedJennifer L MartéYo-Ting Tsai Renee N DonahueElizabeth LampingShania BaileyAndrew WeismanBeatriz Walter-RodriguezRena ItoYulia VugmeysterMasashi SatoAndreas MachlJeffrey Schlom James L Gulley

Published in: Journal for immunotherapy of cancer (2024)

Bintrafusp alfa was observed to have modest clinical activity and manageable safety, and was associated with notable immunologic changes involving modulation of the tumor immune microenvironment in patients with advanced NSCLC.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
replacement therapy
stem cells
small cell lung cancer
transforming growth factor
cancer therapy
tyrosine kinase
drug delivery
signaling pathway
brain metastases
epithelial mesenchymal transition
smoking cessation